Hot Blue Chip Stocks To Own For 2023


When it comes to selecting dividend stocks to buy, investors can take their pick: high yield stocks, blue chip stocks with safe payouts, stocks with high dividend growth rates, value stocks; the list goes on.

But selecting undervalued dividend stocks is particularly advantageous for a variety of reasons, not the least of which is that dividend yield is higher when a stock’s price is lower, as they move inversely.

Here are 3 undervalued dividend stocks to buy for high total returns:

Triton International (NYSE:TRTN) Perrigo Company (NYSE:PRGO) LyondellBasell Industries (NYSE:LYB)

A low valuation also means a better chance for higher capital appreciation (in addition to the income received) when that undervalued stock sees its valuation multiples rise.

Dividend Stocks to Buy: Triton International (TRTN) Source: VladSV / Shutterstock.com


Our first stock is Triton International, a company that acquires, leases and sells intermodal containers and chassis to shipping lines, manufacturers and freight forwarders. Triton leases many types of containers including tanks, specialty, dry and refrigerated. It also trades in containers, buying and selling on the open market.

Hot Blue Chip Stocks To Own For 2023: DraftKings Inc.(DKNG)

DraftKings Inc. operates as a digital sports entertainment and gaming company in the United States. It operates through two segments, Business-to-Consumer and Business-to-Business. The company provides users with daily sports, sports betting, and iGaming opportunities. It is also involved in the design, development, and licensing of sports betting and casino gaming platform software for online and retail sportsbook, and casino gaming products. The company distributes its product offerings through various channels, including traditional websites and direct app downloads, as well as direct-to-consumer digital platforms, such as the Apple App store and the Google Play store. DraftKings Inc. was founded in 2011 and is headquartered in Boston, Massachusetts.


Advisors’ Opinion:

  • [By ]

    Instead, I’d look at American sports betting stocks which, along with a lot of other U.S. stocks, are on sale right now, but the difference here is they’re worth buying. I’m on the record as loving DraftKings Inc. (NASDAQ: DKNG), and the stock is looking mighty nice right now; Monday’s massive, global sell-off knocked nearly 5% off the price, taking it well below $60. I’d be a buyer here.

  • [By ]

    You can now bet in two dozen states, and in more than half of them, you can bet online or on your phone. To settle those bets, online bookmakers like DraftKings (ticker: DKNG) need play-by-play game data, and that’s spawned sports-data suppliers like Genius Sports (GENI), which listed in April on the NYSE.

  • [By ]

    DraftKings (NASDAQ:DKNG) had its price objective raised by Craig Hallum from $60.00 to $70.00 in a report published on Tuesday morning, The Fly reports. Craig Hallum currently has a buy rating on the stock.

Hot Blue Chip Stocks To Own For 2023: Takeda Pharmaceutical Company L(TAK)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.


Advisors’ Opinion:

  • [By Josh Enomoto]

    However, Bayer’s overlooked nature brings opportunity for contrarians. Gurufocus.com labels Bayer modestly undervalued. To be fair, the company’s three-year revenue growth rate stands just above middle of the road. However, Bayer features no debt, giving it incredible flexibility. As well, it commands an operating margin of 21.7%, ranked better than 87.5% of competing pharmas.

    Takeda Pharmaceutical (TAK) Source: Sisacorn / Shutterstock.com


    Representing one of the largest pharmaceutical companies in the world by revenue, Takeda Pharmaceutical (NYSE:TAK) focuses on several advanced therapeutics. As it states on its website:

  • [By Thomas Niel]

    Most recently, this was seen with the company’s deal with Takeda Pharmaceutical (NYSE:TAK) in Japan. As InvestorPlace’s Samuel O’Brient reported on Sept. 7, the company is licensing its vaccine to Takeda, which will manufacture 150 million doses for the Japanese government. This deal is particularly promising in two ways.

Hot Blue Chip Stocks To Own For 2023: Chunghwa Telecom Co., Ltd.(CHT)


Chunghwa Telecom Co., Ltd. provides telecommunication services primarily in Taiwan. The companyÂ’s Domestic Fixed Communications Business segment provides local telephone services, domestic long distance telephone services, broadband access, and related services. Its Mobile Communications Business segment is involved in mobile services, sales of mobile handsets and data cards, and related services. The companyÂ’s Internet Business segment provides HiNet services and related services. Its International Fixed Communications Business segment offers international long distance telephone services and related services. Chunghwa Telecom Co., Ltd. was founded in 1996 and is based in Taipei, Taiwan.


Advisors’ Opinion:

  • [By Logan Wallace]

    Harsco Co. (NYSE:HSC) has earned a consensus recommendation of “Buy” from the six analysts that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $32.33.

  • [By Ethan Ryder]

    HashCoin (CURRENCY:HSC) traded up 2.7% against the US dollar during the 24-hour period ending at 20:00 PM ET on March 6th. HashCoin has a total market cap of $1.21 million and approximately $1,110.00 worth of HashCoin was traded on exchanges in the last 24 hours. One HashCoin token can currently be purchased for $0.0001 or 0.00000002 BTC on exchanges including BCEX and Gate.io. In the last week, HashCoin has traded 0.4% lower against the US dollar.

  • [By Stephan Byrd]

    Harsco Co. (NYSE:HSC) has earned an average recommendation of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $29.50.

  • [By Joseph Griffin]

    HashCoin (CURRENCY:HSC) traded 2.5% lower against the US dollar during the 1 day period ending at 20:00 PM ET on September 30th. HashCoin has a total market capitalization of $0.00 and $28,133.00 worth of HashCoin was traded on exchanges in the last day. One HashCoin token can currently be purchased for approximately $0.0004 or 0.00000005 BTC on exchanges including Gate.io and BCEX. Over the last week, HashCoin has traded down 5.5% against the US dollar.

Leave a Reply

Your email address will not be published.